New Delhi: Bain Capital-backed Emcure Pharmaceuticals is set to launch its initial public offering (IPO) on July 3.
According to the red herring prospectus (RHP), the initial share sale will end on July 5 and bidding for anchor investors will open for one day on July 2.
The IPO comprises issuance of fresh equity shares worth Rs 800 crore and offer for sale (OFS) of 1.14 crore equity shares by promoters and existing shareholders.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, a subsidiary of US-based private equity major Bain Capital.
Currently, Satish Mehta holds 41.85 percent stake in the company and BC Investments holds 13.07 percent.
The proceeds from the fresh issue will be used for repayment of debt and general corporate purposes.
Pune-based firm Emcure Pharmaceuticals is engaged in the development, manufacturing and global marketing of a wide range of pharmaceutical products across several key therapeutic areas.
Earlier this month, the company had received SEBI's approval to launch the initial share sale. Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JP Morgan India are the book-running lead managers to the issue. The company's equity shares are expected to be listed on BSE and NSE on July 10.
According to the red herring prospectus (RHP), the initial share sale will end on July 5 and bidding for anchor investors will open for one day on July 2.
The IPO comprises issuance of fresh equity shares worth Rs 800 crore and offer for sale (OFS) of 1.14 crore equity shares by promoters and existing shareholders.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, a subsidiary of US-based private equity major Bain Capital.
Currently, Satish Mehta holds 41.85 percent stake in the company and BC Investments holds 13.07 percent.
The proceeds from the fresh issue will be used for repayment of debt and general corporate purposes.
Pune-based firm Emcure Pharmaceuticals is engaged in the development, manufacturing and global marketing of a wide range of pharmaceutical products across several key therapeutic areas.
Earlier this month, the company had received SEBI's approval to launch the initial share sale. Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JP Morgan India are the book-running lead managers to the issue. The company's equity shares are expected to be listed on BSE and NSE on July 10.
